H.C. Wainwright downgraded Taiwan Liposome from Buy to Neutral and set a new price target of $7.50 from $11.00 previously

Laidlaw downgraded Taiwan Liposome from Buy to Hold

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with Endo International plc (NASDAQ:ENDP) for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain. Under the terms of the agreement, signed with Endo's subsidiary Endo Ventures Limited (EVL), TLC will primarily be responsible for the development of the product and EVL will primarily be responsible fo

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy. TLC599 is a proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) intended for the treatment of osteoarthritis pain. The results demonstrated statistically significantly reduced pain scores and oral pain medication use for up to 6 months wit

This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exemption from the registration requirements of the Securities Act provided by Rule 802 thereof. No public offering of such securities will be made in the United States. Such transaction has not been and

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. "The second quarter of 2021 was marked mainly by the timely approval of our liposomal amphotericin B product in India and the immediate partnerships for their commercialization and sales in the territory," commented George Yeh, President of TLC. "We are grateful to have the ability to be of assistance in this humanitarian crisis brought about by the COVID-19 pandemic by fulfilli

TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (NASDAQ:TLC, TWO: 4152, "the company"))), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced details of the company's board-approved stock swap transactions with Woods Investment Company, Ltd. ("Woods") at a press conference held at 4:00pm Taipei time at the Taipei Exchange (TPEx). Details of the stock swap transactions are as follows: In response to the company's long-term development plan and realization of shareholders' investment, the company's board of directors passed a resolution on July 5, 2021, for conducting a stock swap t

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (NASDAQ:TLC, TWO: 4152))), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of Zydus Cadila group (Zydus) (NSE: CADILAHC), an innovative, global pharmaceutical group that discovers, develops, manufactures and markets a broad range of healthcare therapies, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC™ on a non-exc

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (NASDAQ:TLC, TWO: 4152))), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Central Drugs Standard Control Organization (CDSCO) of India has approved the New Drug Application (NDA) of Amphotericin B Liposome for Injection 50mg (known as Ampholipad® in Taiwan and AmphoTLC™ in India) for immediate importation per approved usage and indication, to aid in the country's emergency of acute liposomal amphotericin B shortage. "AmphoTLC™ is the first and only complex generic drug to have achieved bioequivalence to Gilea

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (NASDAQ:TLC, TWO: 4152))) that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society for Aerosols in Medicine (ISAM) Congress. Pharmacokinetic studies on inhalable liposomal GS-441524 (named ISPM21) and inhalable liposomal hydroxychloroquine (named ISPM19) showed significantly higher concentrations in the lungs than their conventional counterparts, giving ISPM21 and ISPM19 potential as prophylaxis and/or

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 03, 2021 (GLOBE NEWSWIRE) -- TLC (NASDAQ:TLC, TWO: 4152))), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it once again ranks in the Top 5% in Corporate Governance Evaluation amongst all Taiwan Stock Exchange Corporation (TWSE) and Taipei Exchange (TPEx) listed companies. This marks the seventh consecutive year TLC has won the prestigious status since the establishment of the evaluation system in 2015, and TLC remains the only biotech company to have gained such an honor. In addition, TLC also ranks in the Top 5% in the newly added, non-industry

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 26, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (NASDAQ:TLC, TWO: 4152))) that specializes in the development of inhalable liposome formulation programs, announced today that a late-breaking abstract describing the potential advantages of ISPM21 and ISPM19 has been accepted by the scientific committee for poster presentation at the 23rd International Society for Aerosols in Medicine (ISAM) Congress. The poster, titled "A Strategy to Treat COVID-19 with Targeted Delivery of Inhalable Liposomal Antiviral Drugs", has a poster number of 072 (New Devices and Emerging Therapies) and will be posted both on the website (www.is

SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

SC 13D - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

SC 13G - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

SC 13G/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)